Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

• ADP/ATP translocase in the mitochondria, ultimately leading to KCs apoptosis. When encapsulated in liposome in combination with nintedanib, a triple tyrosine kinase inhibitor, there is also a reduction in the secretion of inflammatory cytokines, which enhances the antifibrotic effects. This has been

Mechanistic insights into endosomal escape by sodium oleate-modified liposomes

• Ebrahim Sadaqa,
• Satrialdi,
• Fransiska Kurniawan and
• Diky Mudhakir

Beilstein J. Nanotechnol. 2024, 15, 1667–1685, doi:10.3762/bjnano.15.131

• complexes with liposomal components, enhancing both liposome stability and drug encapsulation. To gain deeper insight into the mechanisms underpinning SO’s potential as an endosomal escape agent, molecular dynamics (MD) simulations have emerged as an indispensable computational tool. These simulations

• . The SO-Lipo variant was enriched with 10 mol % sodium oleate incorporated into the lipid blend before the liposome assembly process. Divergently, the fabrication of AUR-Lipo involved the post-integration of 135 µM stearylated aurein 1.2 peptide into pre-assembled liposomes, using HEPES buffer as the

• medium. This approach ensures the anchorage of the peptide to the liposome membrane surface. Synthesis of the liposomal formulations was conducted via a refined thin-film hydration technique, as inspired by existing protocols [34]. Initially, the lipids were dissolved in a chloroform and methanol

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• ]. Liposomes Liposomes are another type of DDS that has been extensively investigated over the years [87][88][89]. The structure of a liposome contains a lipid bilayer surrounding an aqueous core, which offers advantages in encapsulating both hydrophobic and hydrophilic substances [90]. The additional

Synthesis, characterization and anticancer effect of doxorubicin-loaded dual stimuli-responsive smart nanopolymers

• Ömür Acet,
• Pavel Kirsanov,
• Burcu Önal Acet,
• Inessa Halets-Bui,
• Dzmitry Shcharbin,
• Şeyda Ceylan Cömert and
• Mehmet Odabaşı

Beilstein J. Nanotechnol. 2024, 15, 1189–1196, doi:10.3762/bjnano.15.96

• ” and “Doxil”. The non-pegylated liposomal doxorubicin Myocet liposomal was approved in the European Union and in Canada for the therapy of metastatic breast cancer in combination with cyclophosphamide [5][6]. The FDA approved Doxil [4]. It was found that liposome-encapsulated DOX is less cardiotoxic

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• the antifibrosis compound myricetin in pro-liposome nanocarriers to improve its solubility, stability, and low oral bioavailability [57]. As illustrated in Figure 3, the surface modification of pro-liposome with ᴅ-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E-TPGS) enhanced the stability

• . 154-155, by R. Böttger et al., “Lipid-based nanoparticle technologies for liver targeting“, pages 79-101, Copyright (2020), with permission from Elsevier. This content is not subject to CC BY 4.0. Schematic illustration of non-targeted pro-liposome myricetin nanocarriers modified with vitamin E-TPGS

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• nanoparticulate vaccine is the anti-malarial Mosquirix™ (RTS, S/AS01), recommended by the World Health Organization in four doses for children in 2021. Mosquirix™ employs a liposome-based adjuvant, AS01 (GlaxoSmithKline) [103] that contains 3-O-desacyl-monophosphoryl lipid A and QS-21, a water-soluble triterpene

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

• Douglas Dourado,
• Thayse Silva Medeiros,
• Éverton do Nascimento Alencar,
• Edijane Matos Sales and
• Fábio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4

• , respectively) and promastigote forms (IC50 values for SNEDDSs A and B, 0.017 and 0.031, respectively). These results evidenced the effectiveness of different SNEDDSs when compared to that of the control AmB-liposome AmBisome, which demonstrated IC50 values 10 times higher for amastigotes and promastigotes [79

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• liposomes (500 mg/kg) could be more efficient than free PZQ treatment. Similar results have been shown in other works that also used liposome with PZQ in different concentrations [50][51][52][53]. In addition, Xie et al. [54] studied the pharmacokinetics of solid lipid nanoparticles composed of castor oil

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

Ethosomal (−)-epigallocatechin-3-gallate as a novel approach to enhance antioxidant, anti-collagenase and anti-elastase effects

• Çiğdem Yücel,
• Gökçe Şeker Karatoprak,
• Sena Yalçıntaş and
• Tuğba Eren Böncü

Beilstein J. Nanotechnol. 2022, 13, 491–502, doi:10.3762/bjnano.13.41

• EGCG [8]. In a previous work from our team, an ethosomal formulation developed with rosmarinic acid showed higher inhibition on collagenase and elastase enzymes compared to that of solution and liposome forms. Data supporting the access of ETHs to the deeper layers of the skin were obtained [22

Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications

• Sepand Tehrani Fateh,
• Lida Moradi,
• Elmira Kohan,
• Michael R. Hamblin and
• Amin Shiralizadeh Dezfuli

Beilstein J. Nanotechnol. 2021, 12, 808–862, doi:10.3762/bjnano.12.64

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• estimate that the high levels of BM accumulation for this liposome formulation were probably due to the presence of 20% DSPG in the liposomal bilayer. This yields an overall anionic surface, which is known to have an affinity for the scavenger receptor on BM macrophages. Other polyanions, such as dextran

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• hydrophilic core. Liposomes can thus be loaded with a wide variety of hydrophilic and lipophilic cargos [151]. Some liposome formulations have already received marketing authorizations, such as Ambisome®, Doxil®, Myocet® or more recently Onivyde™. However, no liposomal formulations have received approval for

Rational design of block copolymer self-assemblies in photodynamic therapy

• Maxime Demazeau,
• Laure Gibot,
• Anne-Françoise Mingotaud,
• Patricia Vicendo,
• Clément Roux and
• Barbara Lonetti

Beilstein J. Nanotechnol. 2020, 11, 180–212, doi:10.3762/bjnano.11.15

Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells

• Mohammad J. Akbar,
• Pâmela C. Lukasewicz Ferreira,
• Melania Giorgetti,
• Leanne Stokes and
• Christopher J. Morris

Beilstein J. Nanotechnol. 2019, 10, 2553–2562, doi:10.3762/bjnano.10.246

• targeting has potential for enhancing drug accumulation in resistant cancer cells. Keywords: bombesin; GRPR; liposome; lung cancer; targeting; Introduction Small-cell lung cancer (SCLC) accounts for approximately one in five lung cancer diagnoses. In spite of global efforts to reduce tobacco smoking in

• the purposes of enhanced liposome delivery to lung cancer. Results and Discussion GRPR as a target in lung cancer The functionality of GRPR in SCLC cells was confirmed by Fura-2 studies in which NCI-H345 or NCI-H82 SCLC cell models were exposed to a dose-range of the canonical GRPR agonist peptide

• those reported for other pegylated liposomes by others [27]. The vesicles were colloidally stable in PBS over 72 h at temperatures of 4, 25 and 37 °C with no significant changes in size, PDI or zeta potential observed (Figure 3a,b). It was noted that the diameter of both liposome formulations was larger

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity

• Sebastian Pieper,
• Hannah Onafuye,
• Dennis Mulac,
• Jindrich Cinatl Jr.,
• Mark N. Wass,
• Martin Michaelis and
• Klaus Langer

Beilstein J. Nanotechnol. 2019, 10, 2062–2072, doi:10.3762/bjnano.10.201

• shown to bypass efflux-mediated drug resistance [25]. This included various nanoparticle and liposome formulations of the ABCB1 substrate doxorubicin that were shown to modify the cellular uptake and intracellular distribution of doxorubicin resulting in enhanced effects against ABCB1-expressing cancer

Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells

• Liang Xu,
• Dekang Xu,
• Ziying Li,
• Yu Gao and
• Haijun Chen

Beilstein J. Nanotechnol. 2019, 10, 1933–1942, doi:10.3762/bjnano.10.189

• analogues have a sterol structure that is very similar to cholesterol. It was reported that Di and lipids formed highly stable complexes at the air–water interface [18]. Therefore, Di and its derivatives could be substituted for cholesterol to form novel stable liposome-like phytosomes. The prepared

• phytosomes were expected to enhance the solubility and bioavailability of the Di derivative for clinical transformation. In this study, we first prepared several Di derivatives and screened the most potent candidate through a preliminary structure–activity relationship study. Then the liposome-like

Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells

• Hannah Onafuye,
• Sebastian Pieper,
• Dennis Mulac,
• Jindrich Cinatl Jr.,
• Mark N. Wass,
• Klaus Langer and
• Martin Michaelis

Beilstein J. Nanotechnol. 2019, 10, 1707–1715, doi:10.3762/bjnano.10.166

• resistance [6]. This includes various nanoparticle and liposome formulations of the ABCB1 substrate doxorubicin [7][8][9][10][11][12]. Here, we here investigated the effects of doxorubicin-loaded human serum albumin (HSA) nanoparticles in ABCB1-expressing neuroblastoma cells. HSA nanoparticles are easy to

Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment

• Cem Varan and
• Erem Bilensoy

Beilstein J. Nanotechnol. 2017, 8, 1446–1456, doi:10.3762/bjnano.8.144

• suppressor gene delivery. Their results showed that the prepared nanoparticles enhanced the delivery of tumor suppressor genes on U87 and U251 glioma cells [24]. Wang et al. used core–shell nanoparticles for drug and gene co-delivery. They prepared magnetic PLGA/polymeric liposome carriers to achieve

Comparison of the interactions of daunorubicin in a free form and attached to single-walled carbon nanotubes with model lipid membranes

• Dorota Matyszewska

Beilstein J. Nanotechnol. 2016, 7, 524–532, doi:10.3762/bjnano.7.46

• between targeting agents and their receptors, such as for example folates and transferrin [7][8]. Additionally, liposomes are also prepared in such a way that simultaneous loading of two drugs into a liposome in order to improve the efficiency of the treatment is possible [9]. Dual drug loading is also

Experiences in supporting the structured collection of cancer nanotechnology data using caNanoLab

• Stephanie A. Morris,
• Sharon Gaheen,
• Michal Lijowski,
• Mervi Heiskanen and
• Juli Klemm

Beilstein J. Nanotechnol. 2015, 6, 1580–1593, doi:10.3762/bjnano.6.161

• . Submitters can enter nanomaterial composition information (Figure 9) including: nanomaterial entities (e.g., dendrimer), functionalizing entities (e.g., small molecule), and chemical associations (e.g., covalent bond). This composition model supports the submission of complex particles (e.g., liposome

Using natural language processing techniques to inform research on nanotechnology

• Nastassja A. Lewinski and
• Bridget T. McInnes

Beilstein J. Nanotechnol. 2015, 6, 1439–1449, doi:10.3762/bjnano.6.149

• trials investigating nano versus non-nano drugs. These include facilitating comparisons between clinical trials testing nano and non-nano drug formulations involving the same active ingredient (e.g., Doxil = pegylated liposome [nano] encapsulated doxorubicin compared to Adriamycin = doxorubicin). In

Fulleropeptide esters as potential self-assembled antioxidants

• Mira S. Bjelaković,
• Tatjana J. Kop,
• Jelena Đorđević and
• Dragana R. Milić

Beilstein J. Nanotechnol. 2015, 6, 1065–1071, doi:10.3762/bjnano.6.107

• antioxidant capacity. The antioxidant activity of 12 fullerene esters (as water soluble fullerosomes, obtained by liposome formation with soybean lecithin [31]) was determined by FOX antioxidant assay [32], using vitamin C and fullerene C60 as reference compounds. The FOX assay is based on the oxidation of

Nanobioarchitectures based on chlorophyll photopigment, artificial lipid bilayers and carbon nanotubes

• Marcela Elisabeta Barbinta-Patrascu,
• Stefan Marian Iordache,
• Ana Maria Iordache,
• Nicoleta Badea and
• Camelia Ungureanu

Beilstein J. Nanotechnol. 2014, 5, 2316–2325, doi:10.3762/bjnano.5.240

• -amino-2,3-dihydro-1,4-phthalazinedione), KH2PO4, Na2HPO4, Tris (tris(hydroxymethyl)aminomethane), HCl, and H2O2were purchased from Merck (Germany). Methanol (99.9%), SWCNTs and the lipids used for the liposome preparation (dipalmitoylphosphatidylcholine, DPPC and cholesterol, Chol) were supplied from

• composition: peptone (Merck, 10 g/L), yeast extract (Biolife, 5 g/L), NaCl (Sigma-Aldrich, 5 g/L) and agar (Fluka, 20 g/L). Synthesis Liposome preparation The hydration method [22] of a thin DPPC film was used to obtain two kinds of multilamellar lipid vesicles (MLVs, 0.5 mM) with and without cholesterol in

• abbreviations used in this work are presented in Table 1. Preparation of the liposome/SWCNT biocomposites Small aliquots of a previously sonicated SWCNT stock suspension (0.9 mg/mL, in PB pH 7.4) were added to a liposome suspension and the resulting mixture was subjected to ultrasound treatment (Hielser

The cell-type specific uptake of polymer-coated or micelle-embedded QDs and SPIOs does not provoke an acute pro-inflammatory response in the liver

• Markus Heine,
• Alexander Bartelt,
• Oliver T. Bruns,
• Denise Bargheer,
• Artur Giemsa,
• Barbara Freund,
• Ludger Scheja,
• Christian Waurisch,
• Alexander Eychmüller,
• Rudolph Reimer,
• Horst Weller,
• Peter Nielsen and
• Joerg Heeren

Beilstein J. Nanotechnol. 2014, 5, 1432–1440, doi:10.3762/bjnano.5.155

• , mice were injected intravenously in the tail vein with 200 µL Clodronate liposome solution (ClodronateLiposomes.org, Amsterdam, Netherland) or empty liposomes as control two days prior to the experiments. Gene expression analysis Gene expression analysis was performed as described [39]. Briefly, total